Toosendanin
Based on 6 publication(s) in Google Scholar
Toosendanin, a triterpenoid extracted from the bark of fruit of Melia toosendan Sieb. et Zucc., possesses analgesic, insecticidal and anti-inflammatory activities.
For research use only. We do not sell to patients.
- Purity: 99.74%
- CAS No.: 58812-37-6
- Formula: C30H38O11
- Molecular Weight:574.62
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Toosendanin
More-
Flow Cytometry
-
Flow Cytometry
-
ELISA
-
WB
-
In Vivo Efficacy Study
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCC1806 | IC50 |
0.019 μM
Compound: 1; TSN
|
Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 36781147] |
| MDA-MB-231 | IC50 |
0.115 μM
Compound: 1; TSN
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 36781147] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Forty-eight male C57BL/6 mice weighing 20-22 g[1].
-
Dosage:0.5 and 1 mg/kg.
-
Administration:Intraperitoneal injection daily for 7 days.
-
Result:Protected against DSS-induced colitis in mice.
Inhibited the expression of proinflammatory cytokines in DSS-induced UC and improved oxidative stress.
Chemical Information
-
CAS No. 58812-37-6
-
Appearance Solid
-
Molecular Weight 574.62
-
Formula C30H38O11
-
Color White to off-white
-
SMILES
C[C@@]1([C@H]2OC(C)=O)[C@@]3(O[C@@H]3C[C@H]1C4=COC=C4)[C@]5(C)[C@H](O)C[C@@]6([H])[C@]([C@@H](OC7)O)(C)[C@H](OC(C)=O)C[C@H](O)[C@]67[C@@]5([H])C2=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Eur J Pharmacol
2024 Jun 15:973:176562. PMID: 38588767
Toosendanin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2024 Jun 15:973:176562. [Abstract]
Toosendanin (TSN) (2.5-20 nM; 48 h) significantly inhibited theproliferation of T-cells activated by anti-human CD3/CD28 antibodies.
Toosendanin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2024 Jun 15:973:176562. [Abstract]
Toosendanin (TSN) (2.5-10 nM; 72 h) arrested the cell cycle of activated T-cells in the G0/G1 phase.
Toosendanin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2024 Jun 15:973:176562. [Abstract]
Toosendanin (TSN) (2.5-10 nM; 48 h) significantly inhibited the secretion of IL-17A and IL-6 levels and promoted IL-10 production by activated T-cells.
Toosendanin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2024 Jun 15:973:176562. [Abstract]
Toosendanin (TSN) (5-20 nM; 1 h) significantly reduced the phosphorylation of P38 MAPK in activated T-cells.
Toosendanin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2024 Jun 15:973:176562. [Abstract]
Toosendanin (TSN) (6 mg/kg; i.p.; 24 h) caused fewer liver lesions and significantly alleviated splenomegaly in C57 mice.
-
Int Immunopharmacol
Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling. [Abstract]2019 Nov;76:105909. PMID: 31520988 -
BMC Complement Med Ther
PLGA-based herb Toosendanin delivery system for efficient therapy of oral squamous cell carcinoma. [Abstract]2025 Jul 2;25(1):217. PMID: 40604940 -
BMC Oral Health
Antitumor effect of toosendanin on oral squamous cell carcinoma via suppression of p-STAT3. [Abstract]2023 Nov 9;23(1):846. PMID: 37946196 -
-
Solvent & Solubility
DMSO : 100 mg/mL (174.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7403 mL | 8.7014 mL | 17.4028 mL | 43.5070 mL |
| 5 mM | 0.3481 mL | 1.7403 mL | 3.4806 mL | 8.7014 mL | |
| 10 mM | 0.1740 mL | 0.8701 mL | 1.7403 mL | 4.3507 mL | |
| 15 mM | 0.1160 mL | 0.5801 mL | 1.1602 mL | 2.9005 mL | |
| 20 mM | 0.0870 mL | 0.4351 mL | 0.8701 mL | 2.1754 mL | |
| 25 mM | 0.0696 mL | 0.3481 mL | 0.6961 mL | 1.7403 mL | |
| 30 mM | 0.0580 mL | 0.2900 mL | 0.5801 mL | 1.4502 mL | |
| 40 mM | 0.0435 mL | 0.2175 mL | 0.4351 mL | 1.0877 mL | |
| 50 mM | 0.0348 mL | 0.1740 mL | 0.3481 mL | 0.8701 mL | |
| 60 mM | 0.0290 mL | 0.1450 mL | 0.2900 mL | 0.7251 mL | |
| 80 mM | 0.0218 mL | 0.1088 mL | 0.2175 mL | 0.5438 mL | |
| 100 mM | 0.0174 mL | 0.0870 mL | 0.1740 mL | 0.4351 mL |